Dr Noopur Raje opens this program with a brief discussion on the basics of multiple myeloma. She describes what the disease is, highlights key risk factors, and explains how she helps educate her patients on their diagnosis. Cynthia Harrington discusses her role as a nurse practitioner when working with multiple myeloma patients and why a team-based approach between healthcare providers and the patient is important.
The combination use of Darzalex in combination with Revlimid, Velcade and Ozurdex demonstrated a higher percentage of stringent complete responses among transplant eligible, newly diagnosed patients with multiple myeloma.
The Food and Drug Administration has granted an accelerated approval to Xpovio in combination with dexamethasone for the treatment of adult patients with relapsed/refractory multiple myeloma who have received more than four prior therapies.
The FDA has approved the combination of Darzalex with Revlimid and dexamethasone (DRd) for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation.
Researchers determined that having difficulty performing at least one instrumental activity of daily living puts older patients at risk of death, unplanned hospitalization and emergency department visits.